Literature DB >> 24761846

Ginsenoside Rg1 induces apoptosis through inhibition of the EpoR-mediated JAK2/STAT5 signalling pathway in the TF-1/ Epo human leukemia cell line.

Jing Li1, Qiang Wei, Guo-Wei Zuo, Jing Xia, Zhi-Mei You, Chun-Li Li, Di-Long Chen.   

Abstract

Ginsenoside Rg1 is one effective anticancer and antioxidant constituent of total saponins of Panax ginseng (TSPG), which has been shown to have various pharmacological effects. Our previous study demonstrated that Rg1 had anti-tumor activity in K562 leukemia cells. The aim of this study was designed to investigate whether Rg1 could induce apoptosis in TF-1/Epo cells and further to explore the underlying molecular mechanisms. Here we found that Rg1 could inhibit TF-1/Epo cell proliferation and induce cell apoptosis in vitro in a concentration and time dependent manner. It also suppressed the expression of EpoR on the surface membrane and inhibited JAK2/STAT5 pathway activity. Rg1 induced up-regulation of Bax, cleaved caspase-3 and C-PAPR protein and down-regulation of Bcl-2 and AG490, a JAK2 specific inhibitor, could enhance the effects of Rg1. Our studies showed that EpoR-mediated JAK2/STAT5 signaling played a key role in Rg1-induced apoptosis in TF-1/Epo cells. These results may provide new insights of Rg1 protective roles in the prevention a nd treatment of leukemia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24761846     DOI: 10.7314/apjcp.2014.15.6.2453

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  9 in total

Review 1.  Potential neuroprotective activity of Ginseng in Parkinson's disease: a review.

Authors:  Elena González-Burgos; Carlos Fernandez-Moriano; M Pilar Gómez-Serranillos
Journal:  J Neuroimmune Pharmacol       Date:  2014-10-29       Impact factor: 4.147

2.  Ginsenoside Rg1 protects human umbilical cord blood-derived stromal cells against tert-Butyl hydroperoxide-induced apoptosis through Akt-FoxO3a-Bim signaling pathway.

Authors:  Ying Liu; Long Yi; Lu Wang; Linbo Chen; Xiongbin Chen; Yaping Wang
Journal:  Mol Cell Biochem       Date:  2016-08-13       Impact factor: 3.396

3.  Rapid preparation of rare ginsenosides by acid transformation and their structure-activity relationships against cancer cells.

Authors:  Kai Quan; Qun Liu; Jin-Yi Wan; Yi-Jing Zhao; Ru-Zhou Guo; Raphael N Alolga; Ping Li; Lian-Wen Qi
Journal:  Sci Rep       Date:  2015-02-26       Impact factor: 4.379

4.  Ginsenoside Rb1 inhibits hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cells by regulating microRNA-25.

Authors:  Dan Liu; Ting Liu; Yue Teng; Wei Chen; Le Zhao; Xu Li
Journal:  Exp Ther Med       Date:  2017-08-04       Impact factor: 2.447

Review 5.  Saponins from Chinese Medicines as Anticancer Agents.

Authors:  Xiao-Huang Xu; Ting Li; Chi Man Vivienne Fong; Xiuping Chen; Xiao-Jia Chen; Yi-Tao Wang; Ming-Qing Huang; Jin-Jian Lu
Journal:  Molecules       Date:  2016-10-05       Impact factor: 4.411

6.  Ginsenoside Rg1 attenuates the inflammation and oxidative stress induced by diabetic nephropathy through regulating the PI3K/AKT/FOXO3 pathway.

Authors:  Hui Liu; Wenli Chen; Ping Lu; Yifei Ma; Xinjun Liang; Yanyan Liu
Journal:  Ann Transl Med       Date:  2021-12

7.  Ginsenoside 20(S)-Rg3 targets HIF-1α to block hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cells.

Authors:  Ting Liu; Le Zhao; Yan Zhang; Wei Chen; Dan Liu; Huilian Hou; Lu Ding; Xu Li
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

8.  The Effect of Transarterial Chemoembolization in Combination With Kang'ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study.

Authors:  Yue-Meng Wan; Yu-Hua Li; Zhi-Yuan Xu; Hua-Mei Wu; Ying Xu; Mei Yang; Xi-Nan Wu
Journal:  Integr Cancer Ther       Date:  2017-11-07       Impact factor: 3.279

Review 9.  Modulation of Multiple Signaling Pathways of the Plant-Derived Natural Products in Cancer.

Authors:  Li-Rui Sun; Wei Zhou; Hong-Mei Zhang; Qiu-Shi Guo; Wei Yang; Bing-Jin Li; Zhi-Hui Sun; Shuo-Hui Gao; Ran-Ji Cui
Journal:  Front Oncol       Date:  2019-11-08       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.